In a third-party analysis conducted by the York Health Economics Consortium, IPD from contemporary studies were evaluated to test the hypothesis that PCI with Impella® support may be associated with a greater extent of revascularization.
Chuck Simonton, MD, reviews that in October 2022 the FDA accepted and closed all Impella post-approval studies for high-risk PCI, cardiogenic shock, post-cardiotomy cardiogenic shock and right heart failure.
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.